Commitment to Innovation and Societal Impact

Yesterday, I listened again to a U.S. Senate Hearing where the costs of pharmaceutical products were discussed. Lars Fruegaard J?rgensen, our CEO at Novo Nordisk A/S, affirmed that "we will never stop developing medicines to defeat diabetes, obesity, and other chronic diseases," as this mission is the very reason Novo Nordisk was founded and continues to exist. The reasons behind the varying prices of medicines worldwide are complex, and understanding this will require more than just one hearing. As a biomedical engineer who joined Novo Nordisk 11 years ago, I chose not just a job in Denmark but a company whose culture I believe in—we are curious and innovate for the benefit of patients and society at large. The Novo Nordisk Foundation, which holds a controlling interest in Novo Nordisk A/S, focuses on Health, Sustainability, and the Life Science Ecosystem. In 2023, the foundation awarded more than DKK 9.1 billion for societal benefits. No other pharmaceutical company has given so much back to society.